Skip to main content

Table 4 Summary of patients reporting any health problem by EQ-5D domain in the PILLAR and ASPIRE studies

From: Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

  EQ-5D domain Study visit PILLAR, n/N (%) ASPIRE, n/N (%)
All simeprevir Placebo/PR All simeprevir Placebo/PR
Mobiity Baseline 21/306 (6.9) 5/77 (6.5) 27/386 (7.0) 6/64 (9.4)
  Week 24 61/285 (21.5) 6/72 (8.3) 80/355 (22.6) 14/51 (27.5)
  Week 48 25/271 (9.3) 11/67 (16.4) 76/352 (21.6) 11/55 (20.0)
  Week 72 16/279 (5.7) 5/68 (7.4) 38/340 (11.2) 11/55 (20.0)
Self-care Baseline 3/306 (1.0) 2/77 (2.6) 5/387 (1.3) 2/64 (3.1)
  Week 24 6/285 (2.1) 2/72 (2.8) 13/354 (3.7) 3/51 (5.9)
  Week 48 5/271 (1.9) 2/68 (2.9) 18/352 (5.1) 5/55 (9.1)
  Week 72 6/279 (2.2) 1/68 (1.5) 9/339 (2.7) 3/55 (5.5)
Usual activities Baseline 32/305 (10.5) 4/77 (5.2) 49/387 (12.6) 9/64 (14.1)
  Week 24 148/284 (52.1) 36/72 (50.0) 159/354 (44.9) 18/51 (35.3)
  Week 48 46/271 (17.0) 31/68 (45.5) 153/351 (43.6) 17/55 (30.9)
  Week 72 36/279 (12.9) 8/68 (11.8) 55/338 (16.3) 12/55 (21.8)
Pain/discomfort Baseline 83/306 (27.1) 17/77 (22.1) 109/385 (28.3) 15/64 (23.4)
  Week 24 154/285 (54.0) 45/72 (62.5) 193/354 (54.5) 21/51 (41.2)
  Week 48 73/271 (27.0) 38/68 (55.9) 188/349 (53.9) 22/55 (40.0)
  Week 72 64/279 (23.0) 19/68 (27.9) 107/337 (31.8) 21/55 (38.2)
Anxiety/ Baseline 71/306 (23.2) 15/77 (19.5) 80/385 (20.8) 11/64 (17.2)
depression Week 24 130/284 (45.7) 39/72 (54.2) 165/355 (46.4) 21/51 (41.2)
  Week 48 65/271 (23.9) 24/68 (35.3) 168/351 (47.9) 20/55 (36.4)
  Week 72 63/279 (22.6) 15/68 (22.0) 94/338 (27.9) 18/55 (32.7)
  1. EQ-5D European Quality of Life 5-Dimensions, PR placebo/peginterferon-α and ribavirin.